- Home
- DTST vs MDCX Comparison
DTST vs MDCX Comparison
Compare DTST & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTST | MDCX |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 15.9M |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DTST | MDCX |
|---|---|---|
| Price | $2.79 | $0.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 10.1K | ★ 5.3M |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3671.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,382,929.00 | N/A |
| Revenue This Year | $25.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.82 | $0.14 |
| 52 Week High | $5.15 | $3.05 |
Technical Indicators
Market Signals| Indicator | DTST | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 34.28 |
| Support Level | $2.85 | $0.15 |
| Resistance Level | $3.15 | $0.36 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 42.42 | 22.96 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.